Outlook Therapeutics faces FDA hurdles for Lytenava's approval in wet AMD, seeking clarity on efficacy requirements while expanding globally.

The fact that this channel exists would in no way help us obtain those medications. In the areas of drugs that are not covered or individuals with high deductibles, this might be a way to save money ...

Lawyers for Susan Monarez are pushing back against efforts to remove her from her position as Director of the CDC. The drama began on August 27, when the official HHS X (formerly Twitter) account ...

Derrick Gastineau, head of marketing at Currax Pharmaceuticals, spoke with Pharmaceutical Executive about the marketing landscape for weight loss medications and how it’s a therapeutic area where its ...

Bayer's Gadoquatrane, a low-dose MRI contrast agent, aims to enhance imaging safety and efficacy for chronic disease patients ...

BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high ...

ACOG reaffirms support for COVID-19 vaccines during pregnancy, challenging recent CDC recommendations and emphasizing ...

Pfizer initiates layoffs at its Bothell site as part of a broader cost-cutting strategy, aiming to enhance R&D efficiency and ...

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic ...

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new ...

Michael Grosberg, vice president of product management, spoke with Pharmaceutical Executive about direct-to-consumer sales ...

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as ...